DDInter698 DDInter1036
Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid]. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]. Etidronic acid was granted FDA approval on 1 September 1977.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Etidronic acid {u} (Compound) resembles {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Risedronic acid
Risedronic acid {u} (Compound) resembles {v} (Compound) Pamidronic acid
Pamidronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Clodronate
Clodronate {u} (Compound) resembles {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Pamidronic acid
Pamidronic acid {u} (Compound) resembles {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Risedronic acid
Risedronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) treats {v} (Disease) Paget's disease of bone
Paget's disease of bone {u} (Disease) is treated by {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) upregulates {v} (Gene) PLSCR1
PLSCR1 {u} (Gene) is upregulated by {v} (Compound) Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) resembles {v} (Compound) Ibandronate
Ibandronate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Etidronic acid {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Mifepristone
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Lenvatinib
Etidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid (Compound) resembles Pamidronic acid (Compound) and Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Clodronate (Compound) and Clodronate (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Pamidronic acid (Compound) and Pamidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) treats Paget's disease of bone (Disease) and Paget's disease of bone (Disease) is treated by Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) upregulates PLSCR1 (Gene) and PLSCR1 (Gene) is upregulated by Isoprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Etidronic acid (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Mifepristone (Compound) and Mifepristone may lead to a major life threatening interaction when taken with Lenvatinib